secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cytek Biosciences, Inc. (CTKB)
CIK:        0001831915
Form:       8-K
Filed at:   2026-05-07T23:59:59+00:00
Accession:  0001193125-26-211948
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cytek Q1 revenue $44.1M (+6% YoY); net loss widens to $18.9M; reaffirms FY guidance
--------------------------------------------------------------------------------

- Total revenue $44.1M (+6% YoY); service revenue $15.4M (+15%).
- Installed base 3,789 instruments (+125 units); TTM recurring revenue 35% of total (up from 31%).
- GAAP net loss $18.9M vs $11.4M; adjusted EBITDA loss $9.1M vs $3.3M loss.
- G&A expenses up 43% YoY driven by litigation, consulting, and bad debt reserves.
- Reaffirms FY2026 revenue guidance $205M-$212M (2-5% growth).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1831915/000119312526211948/0001193125-26-211948-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1831915/000119312526211948/d146722d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-211948

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer